BR0309475A - Derivados de pirazolo-[1,5-a]-pirimidina e inibidores de nad(p)h oxidase que contêm os mesmos - Google Patents
Derivados de pirazolo-[1,5-a]-pirimidina e inibidores de nad(p)h oxidase que contêm os mesmosInfo
- Publication number
- BR0309475A BR0309475A BR0309475-8A BR0309475A BR0309475A BR 0309475 A BR0309475 A BR 0309475A BR 0309475 A BR0309475 A BR 0309475A BR 0309475 A BR0309475 A BR 0309475A
- Authority
- BR
- Brazil
- Prior art keywords
- nad
- pyrimidine derivatives
- oxidase inhibitors
- pyrazolo
- inhibitors containing
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Diabetes (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Endocrinology (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Emergency Medicine (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Ophthalmology & Optometry (AREA)
- Vascular Medicine (AREA)
- Pulmonology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Abstract
"DERIVADOS DE PIRAZOLO-[1,5-a]-PIRIMIDINA E INIBIDORES DE NAD (P) H OXIDASE QUE CONTêM OS MESMOS". Descreve-se um composto representado pela fórmula (Ia) (onde R~ 1a~, R~ 2a~, e R~ 3~ a R~ 5~ são iguais aos definidos no relatório descritivo), um seu pró-medicamento, um seu sal farmaceuticamente aceitável, ou um seu solvato. Os compostos são úteis na prevenção ou tratamento de doenças relacionadas a NAD (P) H.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2002121519 | 2002-04-23 | ||
PCT/JP2003/005024 WO2003091256A1 (fr) | 2002-04-23 | 2003-04-18 | Derive de pyrazolo[1,5-a]pyrimidine et inhibiteur de la nad(p)h oxydase contenant ledit derive |
Publications (1)
Publication Number | Publication Date |
---|---|
BR0309475A true BR0309475A (pt) | 2005-03-01 |
Family
ID=29267410
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR0309475-8A BR0309475A (pt) | 2002-04-23 | 2003-04-18 | Derivados de pirazolo-[1,5-a]-pirimidina e inibidores de nad(p)h oxidase que contêm os mesmos |
Country Status (11)
Country | Link |
---|---|
US (1) | US7662826B2 (pt) |
EP (1) | EP1505068A4 (pt) |
JP (1) | JP4500055B2 (pt) |
KR (1) | KR20040097375A (pt) |
CN (1) | CN100343255C (pt) |
AU (1) | AU2003227437A1 (pt) |
BR (1) | BR0309475A (pt) |
CA (1) | CA2483306A1 (pt) |
MX (1) | MXPA04010441A (pt) |
TW (1) | TW200404804A (pt) |
WO (1) | WO2003091256A1 (pt) |
Families Citing this family (134)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7119200B2 (en) | 2002-09-04 | 2006-10-10 | Schering Corporation | Pyrazolopyrimidines as cyclin dependent kinase inhibitors |
US8580782B2 (en) | 2002-09-04 | 2013-11-12 | Merck Sharp & Dohme Corp. | Substituted pyrazolo[1,5-a]pyrimidines as cyclin dependent kinase inhibitors |
CA2497539A1 (en) | 2002-09-04 | 2004-03-18 | Schering Corporation | Novel pyrazolopyrimidines as cyclin dependent kinase inhibitors |
US7161003B1 (en) | 2002-09-04 | 2007-01-09 | Schering Corporation | Pyrazolopyrimidines as cyclin dependent kinase inhibitors |
WO2004022559A1 (en) | 2002-09-04 | 2004-03-18 | Schering Corporation | Pyrazolopyrimidines as cyclin dependent kinase inhibitors |
NZ539164A (en) | 2002-09-04 | 2006-04-28 | Schering Corp | Pyrazolopyrimidines as cyclin dependent kinase inhibitors |
US7196078B2 (en) | 2002-09-04 | 2007-03-27 | Schering Corpoartion | Trisubstituted and tetrasubstituted pyrazolopyrimidines as cyclin dependent kinase inhibitors |
US8673924B2 (en) | 2002-09-04 | 2014-03-18 | Merck Sharp & Dohme Corp. | Substituted pyrazolo[1,5-a]pyrimidines as cyclin dependent kinase inhibitors |
ES2283868T3 (es) | 2002-09-04 | 2007-11-01 | Schering Corporation | Compuestos pirazol(1,5-a) pirimidina como inhibidores de quinasa dependiente de ciclina. |
DE10306250A1 (de) * | 2003-02-14 | 2004-09-09 | Aventis Pharma Deutschland Gmbh | Substituierte N-Arylheterozyklen, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel |
US7223788B2 (en) | 2003-02-14 | 2007-05-29 | Sanofi-Aventis Deutschland Gmbh | Substituted N-aryl heterocycles, process for their preparation and their use as medicaments |
MXPA05008955A (es) | 2003-02-28 | 2006-02-22 | Teijin Pharma Ltd | Derivados de pirazolo [1,5-a] pirimidina. |
US20070179161A1 (en) * | 2003-03-31 | 2007-08-02 | Vernalis (Cambridge) Limited. | Pyrazolopyrimidine compounds and their use in medicine |
EP1616862A4 (en) * | 2003-04-18 | 2008-07-16 | Ono Pharmaceutical Co | HETEROCYCLIC NITROGEN COMPOUND AND USE THEREOF |
WO2004110454A1 (ja) * | 2003-06-13 | 2004-12-23 | Ishihara Sangyo Kaisha, Ltd. | アデノシンA2a受容体アゴニストの投与が必要な疾患を治療又は予防するための組成物 |
WO2005049593A2 (en) * | 2003-11-13 | 2005-06-02 | Abbott Laboratories | N-acylsulfonamide apoptosis promoters |
US20070155738A1 (en) | 2005-05-20 | 2007-07-05 | Alantos Pharmaceuticals, Inc. | Heterobicyclic metalloprotease inhibitors |
JP5052518B2 (ja) | 2005-10-06 | 2012-10-17 | シェーリング コーポレイション | プロテインキナーゼインヒビターとしてのピラゾロピリミジン |
EP1873157A1 (en) * | 2006-06-21 | 2008-01-02 | Bayer Schering Pharma Aktiengesellschaft | Pyrazolopyrimidines and salts thereof, pharmaceutical compositions comprising same, methods of preparing same and uses of same |
KR20090047450A (ko) * | 2006-08-04 | 2009-05-12 | 메르츠 파마 게엠베하 운트 코. 카가아 | 치환된 피라졸로피리미딘, 이의 제조 방법 및 의약품으로서의 이의 용도 |
ATE502943T1 (de) * | 2006-09-29 | 2011-04-15 | Novartis Ag | Pyrazolopyrimidine als pi3k-lipidkinasehemmer |
AU2007321924A1 (en) * | 2006-11-20 | 2008-05-29 | Alantos Pharmaceuticals Holding, Inc. | Heterobicyclic metalloprotease inhibitors |
EP2114941B1 (en) * | 2006-12-22 | 2015-03-25 | Astex Therapeutics Limited | Bicyclic heterocyclic compounds as fgfr inhibitors |
US8513276B2 (en) | 2006-12-22 | 2013-08-20 | Astex Therapeutics Limited | Imidazo[1,2-a]pyridine compounds for use in treating cancer |
EP2002835A1 (en) * | 2007-06-04 | 2008-12-17 | GenKyo Tex | Pyrazolo pyridine derivatives as NADPH oxidase inhibitors |
EP2000176A1 (en) * | 2007-06-04 | 2008-12-10 | GenKyo Tex | Tetrahydroindole derivatives as NADPH Oxidase inhibitors |
AR067326A1 (es) * | 2007-05-11 | 2009-10-07 | Novartis Ag | Imidazopiridinas y pirrolo -pirimidinas sustituidas como inhibidores de cinasa de lipido |
JP5372763B2 (ja) * | 2007-09-28 | 2013-12-18 | 協和発酵キリン株式会社 | 皮膚疾患の予防及び/または治療剤 |
GB0720041D0 (en) | 2007-10-12 | 2007-11-21 | Astex Therapeutics Ltd | New Compounds |
GB0720038D0 (en) | 2007-10-12 | 2007-11-21 | Astex Therapeutics Ltd | New compounds |
EP2085398A1 (en) | 2008-02-01 | 2009-08-05 | Merz Pharma GmbH & Co. KGaA | Pyrazolopyrimidines, a process for their preparation and their use as medicine |
GB0810902D0 (en) | 2008-06-13 | 2008-07-23 | Astex Therapeutics Ltd | New compounds |
CA2726844C (en) | 2008-06-20 | 2016-08-30 | Genentech, Inc. | Triazolopyridine jak inhibitor compounds and methods |
US20100048557A1 (en) | 2008-06-20 | 2010-02-25 | Bing-Yan Zhu | Triazolopyridine JAK Inhibitor Compounds and Methods |
EP2165707A1 (en) * | 2008-09-23 | 2010-03-24 | Genkyo Tex Sa | Pyrazolo pyridine derivatives as NADPH oxidase inhibitors |
EP2166009A1 (en) * | 2008-09-23 | 2010-03-24 | Genkyo Tex Sa | Pyrazolo pyridine derivatives as nadph oxidase inhibitors |
EP2166008A1 (en) * | 2008-09-23 | 2010-03-24 | Genkyo Tex Sa | Pyrazolo pyridine derivatives as NADPH oxidase inhibitors |
EP2166010A1 (en) * | 2008-09-23 | 2010-03-24 | Genkyo Tex Sa | Pyrazolo pyridine derivatives as NADPH oxidase inhibitors |
RU2523544C2 (ru) | 2008-10-22 | 2014-07-20 | Эррэй Биофарма Инк. | ЗАМЕЩЕННЫЕ ПИРАЗОЛО[1,5-a]ПИРИМИДИНОВЫЕ СОЕДИНЕНИЯ КАК ИНГИБИТОРЫ ТРК КИНАЗЫ |
EP2348860B1 (en) | 2008-10-31 | 2015-05-27 | Genentech, Inc. | Pyrazolopyrimidine jak inhibitor compounds and methods |
EP2358716B1 (en) * | 2008-11-12 | 2016-01-06 | Merck Sharp & Dohme Corp. | Inhibitors of fatty acid binding protein (fabp) |
US8591943B2 (en) | 2009-04-09 | 2013-11-26 | Merck Sharp & Dohme Corp. | Pyrazolo[1,5-a]pyrimidine derivatives as mTOR inhibitors |
GB0906472D0 (en) | 2009-04-15 | 2009-05-20 | Astex Therapeutics Ltd | New compounds |
GB0906470D0 (en) | 2009-04-15 | 2009-05-20 | Astex Therapeutics Ltd | New compounds |
WO2010126811A1 (en) | 2009-04-27 | 2010-11-04 | Boehringer Ingelheim International Gmbh | Cxcr3 receptor antagonists |
GB0908394D0 (en) | 2009-05-15 | 2009-06-24 | Univ Leuven Kath | Novel viral replication inhibitors |
UA110324C2 (en) | 2009-07-02 | 2015-12-25 | Genentech Inc | Jak inhibitory compounds based on pyrazolo pyrimidine |
US20110030037A1 (en) * | 2009-07-07 | 2011-02-03 | Vadim Olshansky | Zone migration in network access |
AR077468A1 (es) | 2009-07-09 | 2011-08-31 | Array Biopharma Inc | Compuestos de pirazolo (1,5 -a) pirimidina sustituidos como inhibidores de trk- quinasa |
GB0913636D0 (en) | 2009-08-05 | 2009-09-16 | Univ Leuven Kath | Novel viral replication inhibitors |
EP2305679A1 (en) | 2009-09-28 | 2011-04-06 | GenKyoTex SA | Pyrazoline dione derivatives as nadph oxidase inhibitors |
EP2485735B1 (en) | 2009-10-08 | 2015-07-29 | Merck Sharp & Dohme Corp. | Inhibitors of fatty acid binding protein (fabp) |
ES2555393T3 (es) * | 2009-12-18 | 2015-12-30 | Glaxosmithkline Intellectual Property Limited | Nuevos compuestos |
US9452980B2 (en) | 2009-12-22 | 2016-09-27 | Hoffmann-La Roche Inc. | Substituted benzamides |
US8952004B2 (en) | 2010-01-07 | 2015-02-10 | Boehringer Ingelheim International Gmbh | CXCR3 receptor antagonists |
CA2792102C (en) | 2010-03-05 | 2015-06-09 | Kyowa Hakko Kirin Co., Ltd. | Pyrazolopyrimidine derivative |
MY161853A (en) * | 2010-05-03 | 2017-05-15 | Tsh Biopharm Corp Ltd | Pharmaceutical composition and method for treating hypertension |
SI3205654T1 (sl) | 2010-05-20 | 2019-07-31 | Array Biopharma, Inc. | Makrociklične spojine kot inhibitorji TRK kinaze |
WO2012065963A2 (en) | 2010-11-15 | 2012-05-24 | Katholieke Universiteit Leuven | Novel antiviral compounds |
US8748435B2 (en) | 2011-04-01 | 2014-06-10 | Novartis Ag | Pyrazolo pyrimidine derivatives |
WO2012139876A1 (en) | 2011-04-14 | 2012-10-18 | Merz Pharma Gmbh & Co. Kgaa | Enteric formulations of metabotropic glutamate receptor modulators |
WO2012149157A2 (en) | 2011-04-26 | 2012-11-01 | Bioenergenix | Heterocyclic compounds for the inhibition of pask |
EP2781216A4 (en) | 2011-09-02 | 2015-05-27 | Kyowa Hakko Kirin Co Ltd | CHEMOKINREZEPTORAKTIVITÄTSREGLER |
CA2852936A1 (en) | 2011-10-20 | 2013-04-25 | Glaxosmithkline Llc | Substituted bicyclic aza-heterocycles and analogues as sirtuin modulators |
US20140249147A1 (en) * | 2011-10-20 | 2014-09-04 | GlaxoSmithKline, LLC | Substituted Bicyclic Aza-Heterocycles and Analogues as Sirtuin Modulators |
WO2013087808A1 (en) | 2011-12-15 | 2013-06-20 | Merz Pharma Gmbh & Co. Kgaa | Pharmaceutical composition comprising a pyrazolopyrimidme and cyclodextrin |
WO2013087815A1 (en) | 2011-12-15 | 2013-06-20 | Merz Pharma Gmbh & Co. Kgaa | Liquid pharmaceutical composition containing a pyrazolopyrimidine derivative and pharmaceutical uses thereof |
RU2478640C1 (ru) * | 2012-02-07 | 2013-04-10 | Федеральное государственное бюджетное образовательное учреждение высшего профессионального образования "Пермский государственный национальный исследовательский университет" | N-АРИЛ-2,3-ДИАРОИЛ-8,10-ДИМЕТИЛПИРИДО[2',3':3,4]ПИРАЗОЛО[1,5-α]ПИРИМИДИН-4-КАРБОКСАМИДЫ И СПОСОБ ИХ ПОЛУЧЕНИЯ |
US9278973B2 (en) | 2012-10-25 | 2016-03-08 | Bioenergenix Llc | Heterocyclic compounds for the inhibition of PASK |
WO2014066795A1 (en) | 2012-10-25 | 2014-05-01 | Bioenergenix | Heterocyclic compounds for the inhibition of pask |
AU2013344716B2 (en) | 2012-11-16 | 2018-03-01 | University Health Network | Pyrazolopyrimidine compounds |
CN105164124B (zh) | 2012-11-19 | 2017-03-15 | 诺华股份有限公司 | 用于治疗寄生虫疾病的化合物和组合物 |
US8871754B2 (en) | 2012-11-19 | 2014-10-28 | Irm Llc | Compounds and compositions for the treatment of parasitic diseases |
EP2922852A4 (en) * | 2012-11-20 | 2016-05-25 | Discoverybiomed Inc | CFTR SMALL MOLECULE CORRECTIVES |
AU2013348019A1 (en) | 2012-11-20 | 2015-06-04 | Discoverybiomed, Inc. | Small molecule bicyclic and tricyclic CFTR correctors |
JP6401709B2 (ja) | 2012-12-07 | 2018-10-10 | バーテックス ファーマシューティカルズ インコーポレイテッドVertex Pharmaceuticals Incorporated | Atrキナーゼ阻害剤として有用な化合物 |
SG10201707409PA (en) | 2013-03-13 | 2017-10-30 | Forma Therapeutics Inc | Novel compounds and compositions for inhibition of fasn |
EP2970288A1 (en) * | 2013-03-15 | 2016-01-20 | Vertex Pharmaceuticals Incorporated | Compounds useful as inhibitors of atr kinase |
US9663519B2 (en) * | 2013-03-15 | 2017-05-30 | Vertex Pharmaceuticals Incorporated | Compounds useful as inhibitors of ATR kinase |
US8957078B2 (en) * | 2013-03-15 | 2015-02-17 | Vertex Pharmaceuticals Incorporated | Compounds useful as inhibitors of ATR kinase |
TW201542550A (zh) * | 2013-09-06 | 2015-11-16 | Lexicon Pharmaceuticals Inc | 吡唑并[1,5-a]嘧啶基化合物、包含彼之組合物以及使用彼之方法 |
PL407081A1 (pl) | 2014-02-05 | 2015-08-17 | Celon Pharma Spółka Akcyjna | Pochodne pirazolo[1,5-a]pirymidyny jako inhibitory kinazy JAK-2 |
US10342795B2 (en) | 2014-03-27 | 2019-07-09 | Janssen Pharmaceutica Nv | Substituted 4,5,6,7-tetrahydro-pyrazolo[1,5-a]pyrimidine derivatives and 2,3-dihydro-1H-imidazo[1,2-b]pyrazole derivatives as ROS1 inhibitors |
CN106164076B (zh) | 2014-03-27 | 2019-03-26 | 詹森药业有限公司 | 作为ros1抑制剂的化合物 |
WO2015152319A1 (ja) * | 2014-04-02 | 2015-10-08 | 株式会社 三和化学研究所 | 5,7-無置換-ピラゾロ[1,5-a]ピリミジン-6-カルボン酸の製造方法 |
HUE054784T2 (hu) | 2014-05-23 | 2021-09-28 | Hoffmann La Roche | 5-klór-2-difluor-metoxifenil-pirazolopirimidin vegyületek, amelyek JAK-gátlók |
TWI709561B (zh) * | 2014-05-28 | 2020-11-11 | 瑞士商諾華公司 | 新穎吡唑并嘧啶衍生物 |
SI3699181T1 (sl) | 2014-11-16 | 2023-06-30 | Array Biopharma, Inc. | Kristalinična oblika(s)-n-(5-((r)-2-(2,5-difluorofenil)- pirolidin-1-il)-pirazolo(1,5-a)pirimidin-3-il)-3-hidroksipirolidin-1 -karboksamid hidrogen sulfata |
EP3034500A1 (en) * | 2014-12-17 | 2016-06-22 | Genkyotex Sa | Amido thiazole derivatives as NADPH oxidase inhibitors |
JO3637B1 (ar) | 2015-04-28 | 2020-08-27 | Janssen Sciences Ireland Uc | مركبات بيرازولو- وترايازولو- بيريميدين مضادة للفيروسات rsv |
EP3355926A4 (en) | 2015-09-30 | 2019-08-21 | Vertex Pharmaceuticals Inc. | METHOD FOR THE TREATMENT OF CANCER WITH A COMBINATION OF DNA DAMAGING AGENTS AND ATR INHIBITORS |
ES2928164T3 (es) | 2015-10-19 | 2022-11-15 | Incyte Corp | Compuestos heterocíclicos como inmunomoduladores |
WO2017075107A1 (en) | 2015-10-26 | 2017-05-04 | Nanda Nisha | Point mutations in trk inhibitor-resistant cancer and methods relating to the same |
CA3003820A1 (en) * | 2015-11-13 | 2017-05-18 | Novartis Ag | Novel pyrazolo pyrimidine derivatives |
TWI763641B (zh) | 2015-11-19 | 2022-05-11 | 美商英塞特公司 | 作為免疫調節劑之雜環化合物 |
TW201726623A (zh) * | 2015-12-17 | 2017-08-01 | 英塞特公司 | 作為免疫調節劑之雜環化合物 |
KR20180100585A (ko) | 2015-12-22 | 2018-09-11 | 인사이트 코포레이션 | 면역조절제로서의 헤테로사이클릭 화합물 |
SG11201807516UA (en) | 2016-03-17 | 2018-09-27 | Hoffmann La Roche | 5-ethyl-4-methyl-pyrazole-3-carboxamide derivative having activity as agonist of taar |
US10045991B2 (en) | 2016-04-04 | 2018-08-14 | Loxo Oncology, Inc. | Methods of treating pediatric cancers |
EP3439662A1 (en) | 2016-04-04 | 2019-02-13 | Loxo Oncology Inc. | Liquid formulations of (s)-n-(5-((r)-2-(2,5-difluorophenyl)-pyrrolidin-1-yl)-pyrazolo[1,5-a]pyrimidin-3-yl)-3-hydroxypyrrolidine-1-carboxamide |
RU2769448C2 (ru) | 2016-04-15 | 2022-03-31 | Байер Энимэл Хельс ГмбХ | Новые пиразолпиримидиновые производные |
MA44860A (fr) | 2016-05-06 | 2019-03-13 | Incyte Holdings Corp | Composés hétérocycliques utilisés comme immunomodulateurs |
US11214571B2 (en) | 2016-05-18 | 2022-01-04 | Array Biopharma Inc. | Process for the preparation of (S)-N-(5-((R)-2-(2,5-difluorophenyl)pyrrolidin-1-yl)-pyrazolo[1,5-a]pyrimidin-3-yl)-3-hydroxypyrrolidine-1-carboxamide and salts thereof |
US20170342060A1 (en) | 2016-05-26 | 2017-11-30 | Incyte Corporation | Heterocyclic compounds as immunomodulators |
MD3472167T2 (ro) | 2016-06-20 | 2023-02-28 | Incyte Corp | Compuși heterociclici ca imunomodulatori |
US20180016260A1 (en) | 2016-07-14 | 2018-01-18 | Incyte Corporation | Heterocyclic compounds as immunomodulators |
EP3504198B1 (en) | 2016-08-29 | 2023-01-25 | Incyte Corporation | Heterocyclic compounds as immunomodulators |
JOP20190092A1 (ar) | 2016-10-26 | 2019-04-25 | Array Biopharma Inc | عملية لتحضير مركبات بيرازولو[1، 5-a]بيريميدين وأملاح منها |
CR20190317A (es) | 2016-12-22 | 2019-09-13 | Incyte Corp | Compuestos inmunomodulares y métodos de uso |
ES2874756T3 (es) | 2016-12-22 | 2021-11-05 | Incyte Corp | Derivados de triazolo[1,5-A]piridina como inmunomoduladores |
MY197635A (en) | 2016-12-22 | 2023-06-29 | Incyte Corp | Benzooxazole derivatives as immunomodulators |
EP3558973B1 (en) | 2016-12-22 | 2021-09-15 | Incyte Corporation | Pyridine derivatives as immunomodulators |
JOP20190213A1 (ar) | 2017-03-16 | 2019-09-16 | Array Biopharma Inc | مركبات حلقية ضخمة كمثبطات لكيناز ros1 |
CN106866680B (zh) * | 2017-03-31 | 2019-02-01 | 陕西理工大学 | 一种3-芳基-6-甲酰胺吡唑并[1,5-a]嘧啶类化合物及其应用 |
SG11201909243TA (en) | 2017-04-27 | 2019-11-28 | Bayer Animal Health Gmbh | New bicyclic pyrazole derivatives |
JP7256757B2 (ja) | 2017-05-22 | 2023-04-12 | エフ. ホフマン-ラ ロシュ アーゲー | 処置用化合物及び組成物、並びにその使用方法 |
WO2019032720A1 (en) | 2017-08-09 | 2019-02-14 | Sanford Burnham Prebys Medical Discovery Institute | APELIN RECEPTOR AGONISTS AND METHODS OF USE |
EP3479843A1 (en) | 2017-11-01 | 2019-05-08 | GenKyoTex Suisse SA | Use of nox inhibitors for treatment of cancer |
TW201932470A (zh) | 2017-11-29 | 2019-08-16 | 愛爾蘭商健生科學愛爾蘭無限公司 | 具有抗rsv活性之吡唑并嘧啶 |
MX2020008061A (es) | 2018-01-31 | 2020-09-09 | Janssen Sciences Ireland Unlimited Co | Pirazolopirimidinas sustituidas con cicloalquilo que tienen actividad contra vrs. |
HUE061258T2 (hu) | 2018-03-30 | 2023-05-28 | Incyte Corp | Heterociklusos vegyületek mint immunmodulátorok |
ES2957316T3 (es) | 2018-04-23 | 2024-01-17 | Janssen Sciences Ireland Unlimited Co | Compuestos heteroaromáticos que tienen actividad contra VSR |
CR20200614A (es) | 2018-05-11 | 2021-04-27 | Incyte Corp | Compuestos heterocíclicos como inmunomoduladores |
WO2020092395A1 (en) | 2018-10-29 | 2020-05-07 | Forma Therapeutics, Inc. | SOLID FORMS OF (4-(2-FLUORO-4-(1-METHYL-1 H-BENZO[d]IMIDAZOL-5-YL)BENZOYL) PIPERAZIN-1-YL)(1-HYDROXYCYCLOPROPYL)METHANONE |
MA54092A (fr) | 2018-10-30 | 2021-09-08 | Kronos Bio Inc | Composés, compositions et procédés de modulation de l'activité de cdk9 |
AR119624A1 (es) | 2019-08-09 | 2021-12-29 | Incyte Corp | Sales de un inhibidor de pd-1 / pd-l1 |
CR20220190A (es) | 2019-09-30 | 2022-06-15 | Incyte Corp | Compuestos de pirido [3,2-d] primidina como inmunomoduladores |
KR20220101664A (ko) | 2019-11-11 | 2022-07-19 | 인사이트 코포레이션 | Pd-1/pd-l1 억제제의 염 및 결정질 형태 |
IL297963A (en) * | 2020-05-07 | 2023-01-01 | Adorx Therapeutics Ltd | Adenosine a2a receptor antagonists |
US11780836B2 (en) | 2020-11-06 | 2023-10-10 | Incyte Corporation | Process of preparing a PD-1/PD-L1 inhibitor |
IL302590A (en) | 2020-11-06 | 2023-07-01 | Incyte Corp | Process for preparing PD-1/PD-L1 inhibitor and salts and crystalline forms thereof |
TW202233615A (zh) | 2020-11-06 | 2022-09-01 | 美商英塞特公司 | Pd—1/pd—l1抑制劑之結晶形式 |
CN112876482B (zh) * | 2020-12-31 | 2023-07-28 | 中国药科大学 | 一类多取代杂环衍生物、其制备方法及其在医药上的应用 |
WO2023114157A2 (en) * | 2021-12-17 | 2023-06-22 | Merck Sharp & Dohme Llc | Pyrazolopyrimidine derivatives and methods of use thereof for the treatment of herpesviruses |
Family Cites Families (22)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB1568962A (en) * | 1975-10-31 | 1980-06-11 | Beecham Group Ltd | Reparation and compositions containing them (heterocyclic-carbonylamino)pencillins methods for their p |
GB1579362A (en) * | 1977-03-16 | 1980-11-19 | Beecham Group Ltd | 6-(a-heterocyclylcarbonyl amino-acetamido)-penicillins and compositions containing them |
US4155817A (en) * | 1978-08-11 | 1979-05-22 | American Chemical And Refining Company, Inc. | Low free cyanide high purity silver electroplating bath and method |
US4918074A (en) * | 1984-03-12 | 1990-04-17 | Yoshitomi Pharmaceutical Industries, Ltd. | Polyazaheterocycle compounds |
CA1330079C (en) * | 1988-10-13 | 1994-06-07 | Michihiko Tsujitani | Pyrrolo (3,2-e)pyrazolo(1,5-a)pyrimidine derivative and medicine comprising the same |
KR927003595A (ko) * | 1990-10-09 | 1992-12-18 | 오츠카 아키히코 | 피리미딘 유도체, 이의 제조방법 및 안드로겐 저해제 |
EP0641781B1 (en) * | 1991-09-06 | 2000-07-26 | Yoshitomi Pharmaceutical Industries, Ltd. | 4-amino(alkyl)cyclohexane-1-carboxamide compound and use thereof |
JPH069638A (ja) * | 1992-06-19 | 1994-01-18 | Ube Ind Ltd | ピラゾロピリミジン誘導体 |
JPH07242670A (ja) * | 1994-03-08 | 1995-09-19 | Pola Chem Ind Inc | ピロロ[3,2−e]ピラゾロ[1,5−a]ピリミジン誘導体及びこれを含有する循環器系疾患治療剤 |
JPH07267960A (ja) * | 1994-03-28 | 1995-10-17 | Lederle Japan Ltd | ピロロ[3,2−eピラゾロ[1,5−aピリミジン誘導体及びこれを含有する循環器系疾患治療剤 |
BR9606546A (pt) * | 1995-08-02 | 1998-07-14 | Uriach & Cia Sa J | Novas carboxamidas com atividade fungicida |
JP3898296B2 (ja) | 1996-08-28 | 2007-03-28 | ポーラ化成工業株式会社 | ピロロピラゾロピリミジン化合物及びこれを有効成分とする医薬 |
US6228869B1 (en) * | 1996-10-16 | 2001-05-08 | American Cyanamid Company | Ortho-sulfonamido bicyclic hydroxamic acids as matrix metalloproteinase and TACE inhibitors |
US6548524B2 (en) * | 1996-10-16 | 2003-04-15 | American Cyanamid Company | Preparation and use of ortho-sulfonamido bicyclic heteroaryl hydroxamic acids as matrix metalloproteinase and TACE inhibitors |
ES2214728T3 (es) * | 1997-08-22 | 2004-09-16 | F. Hoffmann-La Roche Ag | Derivados de n-aroilfenilalanina. |
US6229011B1 (en) * | 1997-08-22 | 2001-05-08 | Hoffman-La Roche Inc. | N-aroylphenylalanine derivative VCAM-1 inhibitors |
DE69815544T2 (de) * | 1997-10-06 | 2004-05-13 | Wyeth Holdings Corp. | Herstellung und verwendung von ortho-sulfonamido bicyclische heteroaryl hydroxamsäure derivate als matrix-metalloproteinase und tace inhibitoren |
DZ2796A1 (fr) * | 1998-05-21 | 2003-12-01 | Smithkline Beecham Corp | Composés à fonction bis-aminométhyl-carbonyle nouveaux, procédé pour leur préparation et compositions pharmaceutiques les contenant. |
JP2001302666A (ja) * | 1999-09-21 | 2001-10-31 | Nissan Chem Ind Ltd | アゾール縮合ヘテロ環アニライド化合物及び除草剤 |
KR100858642B1 (ko) * | 2000-05-22 | 2008-09-17 | 아벤티스 파마슈티칼스 인크. | 트립타제 억제제로서 사용하기 위한 아릴메틸아민 유도체 |
EP1318974A2 (en) * | 2000-09-21 | 2003-06-18 | Pfizer Products Inc. | Resorcinol derivatives |
FR2815030A1 (fr) * | 2000-10-05 | 2002-04-12 | Lipha | Derives nitroso de la diphenylamine, compositions pharmaceutiques les contenant et leur utilisation pour la preparation de medicaments |
-
2003
- 2003-04-18 MX MXPA04010441A patent/MXPA04010441A/es not_active Application Discontinuation
- 2003-04-18 CN CNB038144832A patent/CN100343255C/zh not_active Expired - Fee Related
- 2003-04-18 BR BR0309475-8A patent/BR0309475A/pt not_active IP Right Cessation
- 2003-04-18 CA CA002483306A patent/CA2483306A1/en not_active Abandoned
- 2003-04-18 WO PCT/JP2003/005024 patent/WO2003091256A1/ja active Application Filing
- 2003-04-18 EP EP03717663A patent/EP1505068A4/en not_active Withdrawn
- 2003-04-18 JP JP2003587814A patent/JP4500055B2/ja not_active Expired - Fee Related
- 2003-04-18 KR KR10-2004-7016874A patent/KR20040097375A/ko not_active Application Discontinuation
- 2003-04-18 AU AU2003227437A patent/AU2003227437A1/en not_active Abandoned
- 2003-04-18 US US10/511,840 patent/US7662826B2/en not_active Expired - Fee Related
- 2003-04-23 TW TW092109471A patent/TW200404804A/zh unknown
Also Published As
Publication number | Publication date |
---|---|
WO2003091256A1 (fr) | 2003-11-06 |
AU2003227437A1 (en) | 2003-11-10 |
US7662826B2 (en) | 2010-02-16 |
EP1505068A1 (en) | 2005-02-09 |
MXPA04010441A (es) | 2005-02-14 |
JPWO2003091256A1 (ja) | 2005-09-02 |
CN1662537A (zh) | 2005-08-31 |
JP4500055B2 (ja) | 2010-07-14 |
EP1505068A4 (en) | 2008-03-19 |
CA2483306A1 (en) | 2003-11-06 |
TW200404804A (en) | 2004-04-01 |
KR20040097375A (ko) | 2004-11-17 |
US20060089362A1 (en) | 2006-04-27 |
CN100343255C (zh) | 2007-10-17 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR0309475A (pt) | Derivados de pirazolo-[1,5-a]-pirimidina e inibidores de nad(p)h oxidase que contêm os mesmos | |
WO2005037836A3 (en) | Imidazo ‘1, 5 - a ! pyrazine tyrosine kinase inhibitors | |
NO2015020I2 (no) | Ceritinib eller et farmasøytisk akseptabelt salt derav | |
AP1911A (en) | Pyrrolo[2,3-d]pyrimidine compounds. | |
WO2004056827A3 (en) | Substituted pyrrolo-pyrazole derivatives as kinase inhibitors | |
NO20053144L (no) | Chk-, Pdk- og Akt-inhibitorpyrimidiner, deres fremstilling og anvendelse som famasoytiske midler. | |
TR200001344T2 (tr) | Sikline bağlı kinazların aminotiyazol önleyicileri. | |
WO2005060972A3 (en) | Pyrrolo [2,3-d] pyrimidine compounds for treating transplant rejection | |
WO2001005762A3 (de) | Biphenylderivate, ihre herstellung und ihre verwendung als mtp-inhibitor | |
AU2003284632A1 (en) | Isoquinoline compounds and medicinal use thereof | |
WO2005040170A8 (en) | Pyrrolobenzodiazepine derivatives, compositions comprising the same and methods related thereto | |
NO20051695L (no) | Nye spirokondenserte kinazolinoner og deres anvendelse som fosfodiestereaseinbibitorer | |
MXPA05007516A (es) | Derivados de hexahidropirazino[1,2-a]pirimidina -4, 7-diona sustituidos, metodo para producirlos y su uso como medicamentos. | |
EA200600209A1 (ru) | ПРОИЗВОДНЫЕ ПИРРОЛО[3,4-c]ПИРАЗОЛА, ОБЛАДАЮЩИЕ АКТИВНОСТЬЮ КАК ИНГИБИТОРЫ КИНАЗЫ | |
BR0011121A (pt) | Compostos antibacterianos | |
PT1078923E (pt) | Processo para a preparacao de derivados de benzotiofeno | |
WO2004014868A8 (en) | Pyrimidine-2,4-dione derivatives as matrix metalloproteinase inhibitors | |
NO307463B1 (no) | Galantaminderivater, en fremgangsmõte for fremstilling samt deres anvendelse som medikamenter | |
BRPI0416690A (pt) | derivados de pirrol | |
BR0308765A (pt) | Compostos (4,2-dissubstituìdo-tiazol-5-il)amina como inibidores de pde7 | |
MXPA06000401A (es) | Derivados de naftileno como inhibidores de citocromo p450. | |
ZA200900165B (en) | 4-amino-3-arylamino-6-arylpyrazolo[3,4-D]pyrimidine derivatives, methods for their preparation and their use as antiviral agents | |
WO2004043349A3 (en) | Isoxazoline derivatives as inhibitors of matrix metalloproteinases and/or tnf-alpha converting enzyme | |
BR0308807A (pt) | Compostos tiazol-2-il-imina como inibidores de pde-7 | |
MXPA05012772A (es) | Derivados de benzotiazol y uso de los mismos en el tratamiento de enfermedades relacionadas con el receptor a2a de adenosina. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE A 7A E 8A ANUIDADE(S). |
|
B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2116 DE 26/07/2011. |